IBRX vs KRYS: stock comparison and AI forecast
Immunitybio, Inc. (IBRX) and Krystal Biotech, Inc. (KRYS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IBRX Immunitybio, Inc.
- Market Cap
- $8.43B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
KRYS Krystal Biotech, Inc.
- Price
- $295.90 +3.1% · 6M
- Market Cap
- $8.76B
- P/E Ratio
- 40.2x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- IBRX and KRYS have similar market capitalizations ($8.43B and $8.76B).
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IBRX | KRYS |
|---|---|---|
| Market Cap | $8.43B | $8.76B |
| P/E Ratio | – | 40.20x |
| P/B Ratio | – | 6.10x |
| EPS | $-0.50 | $7.36 |
| Book Value/Share | – | $48.50 |
| Revenue/Share | $0.16 | $15.88 |
| FCF/Share | $-0.27 | $10.48 |
Profitability & Margins
| Metric | IBRX | KRYS |
|---|---|---|
| ROE | – | 15.7% |
| ROA | – | 14.2% |
| ROIC | -45.6% | 15.8% |
| Gross Margin | 99.3% | – |
| Operating Margin | -151.9% | 48.4% |
| Net Margin | – | 47.9% |
| EBT Margin | -598.7% | 55.1% |
| Tax Rate | 0.0% | 13.0% |
Financial Health
| Metric | IBRX | KRYS |
|---|---|---|
| Current Ratio | 5.72x | 7.89x |
| Quick Ratio | 5.70x | 7.53x |
| D/E Ratio | – | 0.10x |
| Financial Leverage | – | 1.10x |
| Interest Coverage | -3.1x | – |
| Working Capital | $362M | $980M |
Cash Flow
| Metric | IBRX | KRYS |
|---|---|---|
| Operating Cash Flow | -$281M | $324M |
| Free Cash Flow | -$288M | $310M |
| Capital Spending | -$7M | -$14M |
| OCF Growth YoY | – | 83.8% |
| FCF Growth YoY | – | 87.3% |
| FCF/Sales | -173.8% | 66.0% |
| CapEx/Sales | 4.2% | 3.0% |
Operational Efficiency
| Metric | IBRX | KRYS |
|---|---|---|
| Asset Turnover | 0.26x | 0.30x |
| Receivables Turnover | 3.1x | 3.5x |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 1.4x | 3.1x |
| Days Sales Outstanding | 118 days | 103 days |
| Days Inventory | 647 days | – |
| Payables Period | 18557 days | – |
| Cash Conversion Cycle | -17793 days | – |
Income Statement
| Metric | IBRX | KRYS |
|---|---|---|
| Total Revenue | $166M | $470M |
| Operating Income | -$252M | $228M |
| Net Income | – | $225M |
| R&D Expense | – | $60M |
| SG&A Expense | – | $156M |
| Cost of Goods Sold | $1M | – |
Dividend & Shareholder Information
| Metric | IBRX | KRYS |
|---|---|---|
| Shares Outstanding | 1060M | 30M |
| Net Income Growth | – | 13.2% |
| EPS Growth | – | 1.7% |
IBRX vs KRYS: stock comparison and AI forecast
Which is bigger, IBRX or KRYS?
IBRX and KRYS have similar market capitalizations ($8.43B and $8.76B).
Which one does Intratio's AI model rank higher, IBRX or KRYS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.